aripiprazole has been researched along with Refractory Depression in 33 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 27 (81.82) | 24.3611 |
2020's | 6 (18.18) | 2.80 |
Authors | Studies |
---|---|
Cipriani, A; Furukawa, TA; Furukawa, Y; Hamza, T; Ostinelli, EG; Salanti, G | 1 |
Jha, MK; Mathew, SJ | 1 |
Lewis, G | 1 |
Ebell, MH | 1 |
Endo, K; Kodama, W; Terao, I; Tsuge, T | 1 |
Blumberger, DM; Buchalter, ELF; Dixon, D; Karp, JF; Lenze, EJ; Miller, JP; Mulsant, BH; Oughli, HA; Reynolds, CF | 1 |
Aslam, M; Chen, P; Davis, L; Hicks, PB; Iranmanesh, A; Johnson, GR; Jurjus, G; Lauro, K; Michalets, J; Mohamed, S; Pilkinton, P; Rao, SD; Sapra, M; Sevilimedu, V; Thase, M; Wilcox, JA; Zisook, S | 1 |
Blumberger, DM; DiNapoli, EA; Gebara, MA; Karp, JF; Kasckow, J; Lenze, EJ; Mulsant, BH; Reynolds, CF | 1 |
Castle, D; Hope, J; Keks, NA | 1 |
Hasegawa, S; Hida, H; Miyake, Y; Mouri, A; Nabeshima, T; Noda, Y; Ozaki, N; Yamada, K; Yoshimi, A | 1 |
Blumberger, DM; Hsu, JH; Karp, JF; Lenze, EJ; Mulsant, BH; Reynolds, CF; Sanches, M | 1 |
Blumberger, DM; Brown, PJ; Cristancho, P; Karp, JF; Lavretsky, H; Lenard, E; Lenze, EJ; Miller, JP; Montes-Garcia, C; Mulsant, BH; Reynolds, CF; Rollman, BL; Roose, SP | 1 |
Pitchot, W | 1 |
Alpert, JE; Doros, GD; Fava, M; Fisher, LB; Freeman, MP; Henry, M; Huz, I | 1 |
O'Brien, JT; Thomas, A | 1 |
Anderson, SJ; Begley, AE; Blumberger, DM; Butters, MA; Dew, MA; Karp, JF; Lenze, EJ; Mulsant, BH; Newcomer, JW; Reynolds, CF; Stack, JA | 1 |
El Bayoumi, H; Ismail, Z | 1 |
Hategan, A | 1 |
Taylor, WD | 1 |
Aizenstein, HJ; Anderson, SJ; Blumberger, D; Butters, MA; Dew, MA; Diniz, BS; Kaneriya, SH; Karp, JF; Lenze, EJ; Lotrich, F; Mulsant, BH; Reynolds, CF; Robbins-Welty, GA; Smagula, SF | 1 |
Pan, PY; Yeh, CB | 1 |
Chen, P; Davis, LL; Hicks, P; Huang, GD; Iranmanesh, A; Johnson, GR; Mohamed, S; Pilkinton, PD; Rao, S; Sapra, M; Tal, I; Vertrees, JE; Weingart, K; Wilcox, JA; Yoon, J; Zisook, S | 1 |
Das, A; Jha, S; Kumar, P; Kumar, R | 1 |
Arandjelovic, K; Eyre, HA; Lavretsky, H | 1 |
Baker, RA; Fava, M; Matsushima, Y; Okame, T; Perry, P; Weiller, E | 1 |
Cheon, EJ; Koo, BH; Lee, JH; Lee, KH; Lee, SJ; Park, YW; Sung, HM | 1 |
Ivanova, A; Qaqish, B; Schoenfeld, DA | 1 |
Karadağ, F; Tan, D; Unal, F | 1 |
Bschor, T; Erbe, S; Gutwinski, S | 1 |
Dalton, ED; Dording, CM; Fava, M; Mischoulon, D; Pencina, MJ | 1 |
Chen, SJ; Chen, ST; Hsiao, YL; Shen, TW | 1 |
Fava, M; Flynn, M; Harper, L; Iosifescu, D; Levy, M; Mischoulon, D; Pencina, M; Pollack, M; Rickels, K; Witte, J | 1 |
Hori, H; Ikenouchi-Sugita, A; Iwata, N; Katsuki, A; Kishi, T; Nakamura, J; Umene-Nakano, W; Yoshimura, R | 1 |
5 review(s) available for aripiprazole and Refractory Depression
Article | Year |
---|---|
Optimal dose of aripiprazole for augmentation therapy of antidepressant-refractory depression: preliminary findings based on a systematic review and dose-effect meta-analysis.
Topics: Adolescent; Adult; Antidepressive Agents; Aripiprazole; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Humans; Male; Reproducibility of Results | 2022 |
Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug-Related Side Effects and Adverse Reactions; Humans; United States | 2023 |
Comparative efficacy, tolerability and acceptability of intravenous racemic ketamine with intranasal esketamine, aripiprazole and lithium as augmentative treatments for treatment-resistant unipolar depression: A systematic review and network meta-analysis
Topics: Adult; Antidepressive Agents; Aripiprazole; Depression; Depressive Disorder; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Lithium; Network Meta-Analysis | 2024 |
Brexpiprazole: a new leaf on the partial dopamine agonist branch.
Topics: Antipsychotic Agents; Aripiprazole; Depressive Disorder, Treatment-Resistant; Dopamine Agonists; Humans; Quinolones; Schizophrenia; Thiophenes | 2018 |
[Augmentation of antidepressants with atypical antipsychotics in non-delusional unipolar depressed patients with non-response to antidepressant-monotherapy].
Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Treatment-Resistant; Dibenzothiazepines; Double-Blind Method; Drug Therapy, Combination; Humans; Lithium Carbonate; Olanzapine; Patient Compliance; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone | 2012 |
13 trial(s) available for aripiprazole and Refractory Depression
Article | Year |
---|---|
Predicting Remission in Late-Life Major Depression: A Clinical Algorithm Based Upon Past Treatment History.
Topics: Algorithms; Antidepressive Agents; Anxiety Disorders; Aripiprazole; Clinical Decision Rules; Comorbidity; Delayed-Action Preparations; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Humans; Likelihood Functions; Prospective Studies; Recurrence; Treatment Outcome; Venlafaxine Hydrochloride | 2019 |
Impact of Concurrent Posttraumatic Stress Disorder on Outcomes of Antipsychotic Augmentation for Major Depressive Disorder With a Prior Failed Treatment: VAST-D Randomized Clinical Trial.
Topics: Adolescent; Adult; Antidepressive Agents; Aripiprazole; Bupropion; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Single-Blind Method; Stress Disorders, Post-Traumatic; Young Adult | 2020 |
Specific depressive symptoms predict remission to aripiprazole augmentation in late-life treatment resistant depression.
Topics: Aged; Antidepressive Agents; Aripiprazole; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists | 2018 |
Clinical Predictors of Extrapyramidal Symptoms Associated With Aripiprazole Augmentation for the Treatment of Late-Life Depression in a Randomized Controlled Trial.
Topics: Aged; Akathisia, Drug-Induced; Antidepressive Agents; Aripiprazole; Depressive Disorder, Treatment-Resistant; Female; Humans; Late Onset Disorders; Male; Parkinson Disease, Secondary; Risk Factors; Time Factors | 2018 |
Optimizing Outcomes of Treatment-Resistant Depression in Older Adults (OPTIMUM): Study Design and Treatment Characteristics of the First 396 Participants Randomized.
Topics: Aged; Antidepressive Agents; Aripiprazole; Bupropion; Depressive Disorder, Treatment-Resistant; Humans; Lithium Compounds; Multicenter Studies as Topic; Nortriptyline; Pragmatic Clinical Trials as Topic; Treatment Outcome | 2019 |
The Role of Anger/Hostility in Treatment-Resistant Depression: A Secondary Analysis From the ADAPT-A Study.
Topics: Adult; Anger; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Hostility; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Surveys and Questionnaires | 2015 |
Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial.
Topics: Aged; Akathisia, Drug-Induced; Antidepressive Agents; Aripiprazole; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Parkinson Disease, Secondary; Recurrence; Treatment Outcome | 2015 |
Predictors and Moderators of Remission With Aripiprazole Augmentation in Treatment-Resistant Late-Life Depression: An Analysis of the IRL-GRey Randomized Clinical Trial.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety; Aripiprazole; Comorbidity; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Executive Function; Female; Follow-Up Studies; Humans; Male; Middle Aged; Odds Ratio; Predictive Value of Tests; Prognosis; Risk Assessment; Risk Factors; Set, Psychology; Severity of Illness Index; Treatment Failure; Treatment Outcome; Venlafaxine Hydrochloride | 2016 |
Characteristics of U.S. Veteran Patients with Major Depressive Disorder who require "next-step" treatments: A VAST-D report.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Aripiprazole; Bupropion; Comorbidity; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Humans; Male; Middle Aged; United States; Veterans; Young Adult | 2016 |
Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning.
Topics: Antidepressive Agents; Aripiprazole; Bupropion; Central Nervous System Stimulants; Cognition; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Female; Humans; Impulsive Behavior; Male; Middle Aged; Psychiatric Status Rating Scales; Quetiapine Fumarate; Quinolones; Sleep; Thiophenes; Treatment Outcome | 2017 |
Comparison of the Efficacy and Safety of Aripiprazole Versus Bupropion Augmentation in Patients With Major Depressive Disorder Unresponsive to Selective Serotonin Reuptake Inhibitors: A Randomized, Prospective, Open-Label Study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bupropion; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dopamine Uptake Inhibitors; Drug Synergism; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Prospective Studies; Selective Serotonin Reuptake Inhibitors | 2017 |
A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study).
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Constipation; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Models, Statistical; Piperazines; Placebos; Quinolones; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome; United States; Weight Gain; Young Adult | 2012 |
Comparison of the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depressive disorder.
Topics: Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Paroxetine; Piperazines; Psychiatric Status Rating Scales; Quinolones; Sertraline | 2012 |
15 other study(ies) available for aripiprazole and Refractory Depression
Article | Year |
---|---|
Aripiprazole Augmentation in Older Persons with Treatment-Resistant Depression.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Aripiprazole; Depression; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Humans; Treatment Outcome | 2023 |
Augmentation With Aripiprazole or Bupropion, or a Switch to Nortriptyline, Effective for Treatment-Resistant Depression in Older Adults.
Topics: Aged; Aripiprazole; Bupropion; Depression; Depressive Disorder, Treatment-Resistant; Humans; Nortriptyline | 2023 |
Dysfunction of Serotonergic and Dopaminergic Neuronal Systems in the Antidepressant-Resistant Impairment of Social Behaviors Induced by Social Defeat Stress Exposure as Juveniles.
Topics: Animals; Antidepressive Agents; Aripiprazole; Brain; Depressive Disorder, Treatment-Resistant; Desipramine; Disease Models, Animal; Dominance-Subordination; Dopamine; Drug Therapy, Combination; Male; Mice, Inbred C57BL; Mice, Inbred ICR; Norepinephrine; Serotonin; Sertraline; Sexual Maturation; Social Behavior; Stress, Psychological | 2018 |
[Is there a place for the physician's hopelesness in the treatment of depression?].
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Chronic Disease; Depressive Disorder; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Duloxetine Hydrochloride; Humans; Male; Middle Aged; Physician's Role; Piperazines; Quinolones; Remission Induction; Risk Factors; Thiophenes; Treatment Outcome | 2013 |
Management of late-life depression: a major leap forward.
Topics: Antidepressive Agents; Aripiprazole; Depressive Disorder, Treatment-Resistant; Female; Humans; Male | 2015 |
Treatment-resistant depression in later life.
Topics: Aged; Antidepressive Agents; Aripiprazole; Depressive Disorder, Treatment-Resistant; Female; Hospitalization; Humans | 2015 |
ACP Journal Club. In older adults with treatment-resistant depression, adding aripiprazole to venlafaxine increased remission at 12 wk.
Topics: Antidepressive Agents; Aripiprazole; Depressive Disorder, Treatment-Resistant; Female; Humans; Male | 2016 |
Moderators of Remission in Patients With Late-Life Depression: Where Do We Go Next?
Topics: Antipsychotic Agents; Anxiety; Aripiprazole; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Executive Function; Female; Humans; Male; Set, Psychology | 2016 |
Laughter therapy in a geriatric patient with treatment-resistant depression and comorbid tardive dyskinesia.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Combined Modality Therapy; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Female; Humans; Laughter Therapy; Paroxetine; Selective Serotonin Reuptake Inhibitors; Tardive Dyskinesia | 2016 |
Effectiveness of add-on l-methylfolate therapy in a complex psychiatric illness with MTHFR C677 T genetic polymorphism.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Fluoxetine; Humans; Lithium Compounds; Male; Methylenetetrahydrofolate Reductase (NADPH2); Obsessive-Compulsive Disorder; Polymorphism, Genetic; Tetrahydrofolates; Vitamin B Complex | 2016 |
Clinicians' Views on Treatment-Resistant Depression: 2016 Survey Reports.
Topics: Aged; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Attitude of Health Personnel; Bupropion; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Female; Humans; Lithium Compounds; Male; Middle Aged; Psychiatry; Surveys and Questionnaires | 2016 |
Optimality, sample size, and power calculations for the sequential parallel comparison design.
Topics: Antipsychotic Agents; Aripiprazole; Computer Simulation; Data Interpretation, Statistical; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Humans; Piperazines; Placebo Effect; Quinolones; Randomized Controlled Trials as Topic; Research Design; Sample Size | 2011 |
Aripiprazole augmentation treatment in treatment resistant bipolar depression: two patient reports.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Treatment-Resistant; Drug Administration Schedule; Female; Humans; Piperazines; Psychiatric Status Rating Scales; Quinolones | 2011 |
Comparison of academic and nonacademic sites in multi-center clinical trials.
Topics: Academic Medical Centers; Academies and Institutes; Adult; Antipsychotic Agents; Aripiprazole; Boston; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Female; Hospitals, General; Humans; Interview, Psychological; Male; Middle Aged; Multicenter Studies as Topic; Patient Dropouts; Patient Selection; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Risk Factors; Young Adult | 2012 |
The effectiveness and safety of adjunctive aripiprazole in Taiwanese patients with antidepressant-refractory major depressive disorder: a prospective, open-label trial.
Topics: Adolescent; Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Cross-Cultural Comparison; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Quinolones; Thailand; Young Adult | 2012 |